A Breast Cancer Survivor Asking for Hormones

Decline systemic therapy and say why clearly.

• Systemic estrogen, with or without a progestin, is avoided in women with a history of estrogen receptor–positive breast cancer because it can promote recurrence; her tamoxifen does not make this safer and the combination creates competing hormonal effects rather than protection.
• Be direct that this is a "no," not a "let's think about it," but pair it immediately with what you can offer. Patients who hear only a refusal often buy unregulated products online.
• Vaginal estrogen is a separate question. For genitourinary syndrome of menopause in a woman on tamoxifen, low-dose vaginal estradiol is considered acceptably low-risk by oncology and menopause societies after non-hormonal options fail, though it is generally avoided with aromatase inhibitors. If she has dryness or dyspareunia, this is a conversation for her oncologist.
• Do not recommend black cohosh - hepatotoxicity has been reported and efficacy is unproven. Dietary soy is fine; high-dose isoflavone supplements are not established as safe in this population.

Set expectations

• Non-hormonal measures typically reduce hot flashes by roughly half, not eliminate them. Saying so up front prevents the next visit from being a disappointment.

Avoid

• Paroxetine and fluoxetine are strong CYP2D6 inhibitors and reduce conversion of tamoxifen to its active metabolite endoxifen. Bupropion is a moderate inhibitor and a poorer choice here.
• Fezolinetant has no safety data in breast cancer; do not use it in this patient.
• Clonidine is a reasonable option in general but her blood pressure is 118/74 and orthostasis would be a predictable problem.

Reasonable choices

• Venlafaxine 37.5 mg daily titrated to 75 mg is first-line and has the strongest evidence base for hot flashes; it may also help her mood and sleep.
• Escitalopram 10–20 mg or citalopram (maximum 20 mg if over 60, and watch the QT interval) are good alternatives.
• Gabapentin 300 mg at night titrated up if vasomotor symptoms persist, though sedation may worsen her daytime function.
• Oxybutynin 2.5–5 mg twice daily has supporting data; anticholinergic burden is acceptable in a cognitively intact 51-year-old but not a long-term plan.

Non-pharmacologic, with real evidence

• Cognitive behavioral therapy for vasomotor symptoms and clinical hypnosis both outperform placebo and have no drug interactions.
• Weight loss if applicable, regular exercise, layered clothing, cooling the bedroom, and avoiding alcohol and caffeine near bedtime.

Reassess in 4–6 weeks; counsel that benefit builds over weeks and that dose titration is expected.

Sleep

• Her insomnia may be primary rather than purely vasomotor. Screen for sleep apnea and use CBT for insomnia rather than adding a sedative-hypnotic, especially given her occupational demands.

Mood

• PHQ-9 of 9 is the mild range but worth tracking; if venlafaxine is started it can treat both problems, which simplifies the regimen.

Sexual and genitourinary health

• Ask directly about vaginal dryness, dyspareunia, and libido - she will not volunteer it, and it is treatable with lubricants, moisturizers, and possibly vaginal estradiol after oncology discussion.

Tamoxifen-specific surveillance

• Any vaginal bleeding warrants prompt endometrial evaluation.
• Review adherence and the reason for the 5-year course; ask about visual symptoms (retinopathy) and leg swelling or calf pain (thromboembolism).
• Tamoxifen is bone-protective in postmenopausal women, so a DEXA is still reasonable at 51 but does not carry the urgency it would on an aromatase inhibitor.

General prevention

• Blood pressure, lipids, weight, and activity in the context of her cardiac risk after chemotherapy and radiation - this is the visit where survivorship care actually happens.